Isosorbide-based peptidomimetics as inhibitors of hepatitis C virus serine protease
作者:Aline C. Portela、Thalita G. Barros、Camilo H. da S. Lima、Luiza R.S. Dias、Pedro H.R. de A. Azevedo、Anna Sophia C.L. Dantas、Ronaldo Mohana-Borges、Gustavo T. Ventura、Sergio Pinheiro、Estela M.F. Muri
DOI:10.1016/j.bmcl.2017.07.027
日期:2017.8
Hepatitis C infection is a cause of chronic liver diseases such as cirrhosis and carcinoma. The current therapy for hepatitis C has limited efficacy and low tolerance. The HCV encodes a serine protease which is critical for viral replication, and few protease inhibitors are currently on the market. In this paper, we describe the synthesis and screening of novel isosorbide-based peptidomimetic inhibitors
丙型肝炎感染是慢性肝病(如肝硬化和癌)的原因。当前的丙型肝炎疗法疗效有限且耐受性低。HCV编码对病毒复制至关重要的丝氨酸蛋白酶,目前市场上很少有蛋白酶抑制剂。在本文中,我们描述了基于异山梨醇的新型拟肽抑制剂的合成和筛选,其中化合物1d,1e和1i在100 µM的体外对蛋白酶的活性具有明显的抑制作用。化合物1e也显示出剂量反应(IC 50 (= 36±3 µM)并以100 µM抑制蛋白酶突变体D168A和V170A,表明它是有希望的HCV NS3 / 4A蛋白酶抑制剂。我们的分子模型研究表明,1e的活性与S2和S4子位点相互作用的变化有关,因为增加的柔韧性有助于降低对D168A的活性,而S4子位点中疏水腔的出现增加了D1A的活性。抑制V170A毒株。